<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03249090</url>
  </required_header>
  <id_info>
    <org_study_id>AFT-39</org_study_id>
    <nct_id>NCT03249090</nct_id>
  </id_info>
  <brief_title>Electronic Patient Reporting of Symptoms During Cancer Treatment</brief_title>
  <acronym>PRO-TECT</acronym>
  <official_title>&quot;PRO-TECT&quot; Patient Reported Outcomes to Enhance Cancer Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alliance Foundation Trials, LLC.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Patient-Centered Outcomes Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of North Carolina</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>American Society of Clinical Oncology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>American Cancer Society, Inc.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Dana-Farber Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Alliance Foundation Trials, LLC.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The current study is designed to test nationally whether patients' outcomes and utilization
      of services can be improved through symptom monitoring via patient-reported outcomes between
      visits.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a cluster RCT at up to 50 sites where randomization will occur in a 1:1 ratio at the
      site level (not at the individual patient level). Therefore, up to 25 sites will be
      randomized to the PRO-TECT intervention arm (patient-reporting of symptoms plus access to
      standardized symptom management guideline), and up to 25 sites will be randomized to the
      control arm (usual care delivery plus access to standardized symptom management guideline).
      Specifically:

      PROCEDURES AT ALL SITES (CONTROL SITES AND INTERVENTION SITES):

        -  Site staff (CRA and Nurse Champion required) will attend the site initiation webinar
           with UNC staff, including training for the PRO-Core online data management system and
           orientation to the symptom management guidelines.

        -  At enrollment, all participants will be given a booklet with patient-level symptom
           advice and a link to the content online.

        -  All participants will receive compensation for participation, mailed to them as gift
           cards by UNC.

        -  CRAs will train all participants how to complete outcomes questionnaires for the trial
           using the PRO-Core online system. Participants will be given a choice to complete these
           in clinic or from home online, or if necessary via paper in clinic (with the CRA
           entering the data into PRO-Core). If the patient does not self-complete this
           information, the CRA will contact them to collect the information and then enter it into
           PRO-Core. The outcomes questionnaires will be completed at baseline; and at month 1 (+/-
           2 weeks); and at months 3, 6, 9, and 12/off-study (+/- 4 weeks each), and will be
           available in English, Spanish, or Mandarin Chinese. At each time point, the CRA will
           contact the participant to remind them about the upcoming questionnaire and offer help.

        -  Chart abstraction will be conducted by CRAs at baseline and at off-study for each
           participant, with data entered into the PRO-Core system. Date of death information will
           additionally be abstracted at 18 and 24 months, and possibly later per the UNC study
           team.

        -  CRAs will be asked to complete a feedback survey (entered by the CRA into the PRO-Core
           online system) and may be asked to participate in a brief telephone debriefing and/or
           site visit.

        -  Accrual will be monitored in a weekly teleconference between the UNC team and site CRAs.

      ADDITIONAL PROCEDURES AT INTERVENTION SITES ONLY:

        -  At baseline, CRAs will also train patients to self-report symptoms and physical
           functioning using the PRO-Core system weekly for up to a year, with a choice to do this
           online or via an automated telephone system (patient choice), and a choice of English,
           Spanish, or Mandarin Chinese.

        -  Whenever a concerning symptom is reported, an automated &quot;email alert&quot; notification will
           be sent to the site CRA. The CRA will forward the email alert to the responsible
           clinical nurse (or other covering clinician) and CC the site's Nurse Champion. Within 72
           hours, the CRA will document what action(s), if any, were taken by the nurse in response
           to the alert (entered by the CRA into a form in the PRO-Core system).

        -  A symptom report will be printed/generated by the site CRA whenever the patient has a
           clinic visit, and will be given to the oncologist and nurse caring for the patient.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 30, 2017</start_date>
  <completion_date type="Anticipated">September 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Physical Functioning</measure>
    <time_frame>3 months</time_frame>
    <description>Physical functioning will be measured via the QLQ-C30</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>Based on the number of events observed. Overall survival will be compared between arms using a stratified log-rank rest.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Emergency room/hospital utilization</measure>
    <time_frame>12 months</time_frame>
    <description>Emergency room/hospitalization will be compared between arms using stratified Fine-Gray competing risk regression with death a competing risk</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of cancer treatment</measure>
    <time_frame>12 months</time_frame>
    <description>Duration of cancer treatment will be compared between arms using stratified Fine-Gray competing risk regression with death as a competing risk</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health-related quality of life and symptom burden time</measure>
    <time_frame>3 months</time_frame>
    <description>Measured by QLQ-C30</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Satisfaction/Communication</measure>
    <time_frame>3 months</time_frame>
    <description>Measured with Patient Satisfaction Questionnaires</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Advanced Cancer</condition>
  <condition>Metastatic Cancer</condition>
  <arm_group>
    <arm_group_label>patient reporting symptoms + symptom guidelines</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients report symptoms weekly via web or automated telephone system. Email alerts to nurses for severe/worsening symptoms; printouts for clinicians at visits. Evidence based symptom management pathways provided to patients and clinicians.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Usual care delivery + symptom guidelines</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Evidence-based symptom management pathways provided to patients and clinicians</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Patient Reporting of Symptoms</intervention_name>
    <description>At baseline, CRAs will train patients to self-report symptoms and physical functioning weekly for up to a year, with a choice to do this online or via an automated telephone system (patient choice), and a choice of English, Spanish, or Mandarin Chinese.
Whenever a concerning symptom is reported, an automated &quot;email alert&quot; notification will be sent to the site CRA. The CRA will forward the email alert to the responsible clinical nurse (or other covering clinician) and CC the site's Nurse Champion. Within 72 hours, the CRA will document what action(s), if any, were taken by the nurse in response to the alert (entered by the CRA into a form in the PRO-Core system).
A symptom report will be printed/generated by the site CRA whenever the patient has a clinic visit, and will be given to the oncologist and nurse caring for the patient.</description>
    <arm_group_label>patient reporting symptoms + symptom guidelines</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Usual Care Delivery</intervention_name>
    <description>Patients receive routine cancer care delivery with no additional systematic monitoring of symptoms</description>
    <arm_group_label>Usual care delivery + symptom guidelines</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Standardized symptom management guidelines</intervention_name>
    <description>At baseline, the CRA will provide all participants with a symptom advice booklet, based on best available evidence, existing guidelines, and expert consensus.
Nurses involved with the clinical care of participants in this study will be provided with access to evidence-based symptom management pathways.</description>
    <arm_group_label>patient reporting symptoms + symptom guidelines</arm_group_label>
    <arm_group_label>Usual care delivery + symptom guidelines</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Adults (21+) with advanced/metastatic cancer of any type (EXCEPT leukemia or indolent
             [slow growing] lymphoma)

          2. Receiving outpatient systemic cancer treatment for non-curative/palliative intent,
             including chemotherapy, targeted therapy, or immunotherapy.

          3. Enrolled at any point in their treatment trajectory, meaning during any line of
             treatment, and at any point during a course or cycle of treatment.

          4. Can understand English, Spanish, and/or Mandarin Chinese.

        Exclusion Criteria:

          1. Cognitive deficits that would preclude understanding of consent form and/or
             questionnaires.

          2. Current participation in a therapeutic clinical trial (because these often involve PRO
             questionnaires and intensive monitoring).

          3. Patients being treated with curative intent (e.g., adjuvant chemotherapy for breast,
             lung, or ovarian cancer; primary curative therapy for testis cancer or lymphoma).

          4. Receiving hormonal therapy only (e.g., tamoxifen or aromatase inhibitors in breast
             cancer; androgen deprivation therapy in prostate cancer; or octreotide in
             neuroendocrine cancers)

          5. Indolent lymphomas (due to their prolonged time courses that may be minimally
             symptomatic).

          6. Leukemias (time courses inconsistent with other tumor types in chronic and acute
             leukemias).

          7. Does not understand English, Spanish, or Mandarin Chinese.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ethan Basch, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of North Carolina, Chapel Hill</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Edward Habermehl</last_name>
    <phone>617-732-8727</phone>
    <email>info@alliancefoundationtrials.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Trini Ajazi</last_name>
    <phone>617-732-8727</phone>
    <email>info@alliancefoundationtrials.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Illinois CancerCare-Peoria</name>
      <address>
        <city>Peoria</city>
        <state>Illinois</state>
        <zip>61615</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Madhuri Bajaj, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medical Oncology and Hematology Associates-Des Moines</name>
      <address>
        <city>Des Moines</city>
        <state>Iowa</state>
        <zip>50309</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Behrens, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Missouri Baptist Medical Center</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63131</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bryan Faller, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>New Hampshire Oncology Hematology PA-Hooksett</name>
      <address>
        <city>Hooksett</city>
        <state>New Hampshire</state>
        <zip>03106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Douglas Weckstein, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>WellSpan Health-York Cancer Center</name>
      <address>
        <city>York</city>
        <state>Pennsylvania</state>
        <zip>17403</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dan Sotirescu, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Basch E. Toward patient-centered drug development in oncology. N Engl J Med. 2013 Aug 1;369(5):397-400. doi: 10.1056/NEJMp1114649. Epub 2013 Jul 3.</citation>
    <PMID>23822654</PMID>
  </reference>
  <reference>
    <citation>Reilly CM, Bruner DW, Mitchell SA, Minasian LM, Basch E, Dueck AC, Cella D, Reeve BB. A literature synthesis of symptom prevalence and severity in persons receiving active cancer treatment. Support Care Cancer. 2013 Jun;21(6):1525-50. doi: 10.1007/s00520-012-1688-0. Epub 2013 Jan 12. Review.</citation>
    <PMID>23314601</PMID>
  </reference>
  <reference>
    <citation>Henry DH, Viswanathan HN, Elkin EP, Traina S, Wade S, Cella D. Symptoms and treatment burden associated with cancer treatment: results from a cross-sectional national survey in the U.S. Support Care Cancer. 2008 Jul;16(7):791-801. doi: 10.1007/s00520-007-0380-2. Epub 2008 Jan 17.</citation>
    <PMID>18204940</PMID>
  </reference>
  <reference>
    <citation>Cleeland CS, Zhao F, Chang VT, Sloan JA, O'Mara AM, Gilman PB, Weiss M, Mendoza TR, Lee JW, Fisch MJ. The symptom burden of cancer: Evidence for a core set of cancer-related and treatment-related symptoms from the Eastern Cooperative Oncology Group Symptom Outcomes and Practice Patterns study. Cancer. 2013 Dec 15;119(24):4333-40. doi: 10.1002/cncr.28376. Epub 2013 Sep 24.</citation>
    <PMID>24114037</PMID>
  </reference>
  <reference>
    <citation>Fromme EK, Eilers KM, Mori M, Hsieh YC, Beer TM. How accurate is clinician reporting of chemotherapy adverse effects? A comparison with patient-reported symptoms from the Quality-of-Life Questionnaire C30. J Clin Oncol. 2004 Sep 1;22(17):3485-90.</citation>
    <PMID>15337796</PMID>
  </reference>
  <reference>
    <citation>Laugsand EA, Sprangers MA, Bjordal K, Skorpen F, Kaasa S, Klepstad P. Health care providers underestimate symptom intensities of cancer patients: a multicenter European study. Health Qual Life Outcomes. 2010 Sep 21;8:104. doi: 10.1186/1477-7525-8-104.</citation>
    <PMID>20858248</PMID>
  </reference>
  <reference>
    <citation>Atkinson TM, Li Y, Coffey CW, Sit L, Shaw M, Lavene D, Bennett AV, Fruscione M, Rogak L, Hay J, GÃ¶nen M, Schrag D, Basch E. Reliability of adverse symptom event reporting by clinicians. Qual Life Res. 2012 Sep;21(7):1159-64. doi: 10.1007/s11136-011-0031-4. Epub 2011 Oct 8.</citation>
    <PMID>21984468</PMID>
  </reference>
  <reference>
    <citation>Fung CH, Hays RD. Prospects and challenges in using patient-reported outcomes in clinical practice. Qual Life Res. 2008 Dec;17(10):1297-302. doi: 10.1007/s11136-008-9379-5. Epub 2008 Aug 18.</citation>
    <PMID>18709564</PMID>
  </reference>
  <reference>
    <citation>Conway PH, Mostashari F, Clancy C. The future of quality measurement for improvement and accountability. JAMA. 2013 Jun 5;309(21):2215-6. doi: 10.1001/jama.2013.4929.</citation>
    <PMID>23736730</PMID>
  </reference>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 1, 2017</study_first_submitted>
  <study_first_submitted_qc>August 10, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 15, 2017</study_first_posted>
  <last_update_submitted>March 16, 2018</last_update_submitted>
  <last_update_submitted_qc>March 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 20, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

